MindBio Therapeutics Targets Growing Demand for Non-Invasive Impairment Detection with AI Voice Analysis
MindBio Therapeutics is developing AI-powered voice analysis to detect drug and alcohol impairment, addressing the need for faster, less invasive workplace testing in mining and other industries as the global market grows.
Workplace impairment testing has seen little innovation over the past several decades, with employers still relying on breathalyzers, saliva tests, urine screening and laboratory analysis. While effective, these methods can be expensive, time-consuming and difficult to scale across large workforces. That challenge is becoming increasingly relevant as regulators and employers place greater emphasis on workplace safety, compliance and operational efficiency.
Against this backdrop, MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is developing a technology platform that takes a different approach. The company has spent several years conducting drug and alcohol research while building artificial intelligence and machine-learning tools. Its platform uses AI-powered voice analysis technology designed to detect drug and alcohol impairment from short speech samples.
The platform analyzes more than 140 acoustic markers and has been trained on a dataset exceeding 50 million data points. Mining operations in South America represent the company's initial commercial focus, where workforce safety and high-volume screening requirements create operational challenges. Potential applications extend beyond mining into aviation, construction, law enforcement, call centers, transportation, and mental health settings.
The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to industry data. MindBio's approach seeks to provide a faster, less invasive alternative to traditional breath, saliva, urine and laboratory-based testing methods.
"Workplace impairment testing remains an essential component of risk management across many industries, but the methods used today have changed relatively little over the past several decades," the company noted in its announcement. The company's voice-based technology could address the need for scalable, non-invasive screening that can be deployed quickly across large workforces.
MindBio Therapeutics is a biotechnology company listed on the Canadian Securities Exchange under the symbol MBIO and on the OTCQB under MBQIF. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://nnw.fm/MBQIF.